pERK Expression in Erlotinib-treated Patients with Advanced Pancreatic Cancer: a Translational Subgroup Analysis From the Randomized AIO-PK0104 Phase III Trial

被引：0

作者：

Boeck, S. ^{[1
,2
]}

Ormanns, S. ^{[3
]}

Laubender, R. P. ^{[4
]}

Jung, A. ^{[3
]}

Siveke, J. T. ^{[5
]}

Haas, M. ^{[1
,2
]}

Kirchner, T. ^{[3
]}

Heinemann, V. ^{[1
,2
]}

机构：

[1] Univ Munich, Klinikum Grosshadern, Dept Internal Med 3, D-8000 Munich, Germany

[2] Ctr Comprehens Canc, Munich, Germany

[3] Univ Munich, Dept Pathol, Munich, Germany

[4] Univ Munich, Inst Med Informat Biometry & Epidemiol, Munich, Germany

[5] Tech Univ Munich, Klinikum Rechts Isar, Dept Internal Med 2, D-8000 Munich, Germany

来源：

EUROPEAN JOURNAL OF CANCER | 2012年 / 48卷

关键词：

D O I：

10.1016/S0959-8049(12)72275-X

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

477

引用

页码：148 / 148

页数：1

共 50 条

[41] Clinical outcome of elderly patients with metastatic colorectal cancer treated with FOLFOXIRI versus FOLFIRI: Subgroup analysis of a randomized phase III trial from the Hellenic Oncology Research Group (HORG)
Vamvakas, L.
Athanasiadis, A.
Karampeazis, A.
Kakolyris, S.
Polyzos, A.
Kouroussis, Ch.
Ziras, N.
Kalbakis, K.
Georgoulias, V.
Souglakos, J.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2010, 76 (01) : 61 - 70
[42] Randomized Phase III Trial of Erlotinib Versus Docetaxel As Second- or Third-Line Therapy in Patients With Advanced Non-Small-Cell Lung Cancer: Docetaxel and Erlotinib Lung Cancer Trial (DELTA)
Kawaguchi, Tomoya
Ando, Masahiko
Asami, Kazuhiro
Okano, Yoshio
Fukuda, Masaaki
Nakagawa, Hideyuki
Ibata, Hidenori
Kozuki, Toshiyuki
Endo, Takeo
Tamura, Atsuhisa
Kamimura, Mitsuhiro
Sakamoto, Kazuhiro
Yoshimi, Michihiro
Soejima, Yoshifumi
Tomizawa, Yoshio
Isa, Shun-ichi
Takada, Minoru
Saka, Hideo
Kubo, Akihito
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (18) : 1902 - 1908
[43] Activity of Eribulin in Patients With Advanced Liposarcoma Demonstrated in a Subgroup Analysis From a Randomized Phase III Study of Eribulin Versus Dacarbazine
Demetri, George D.
Schoffski, Patrick
Grignani, Giovanni
Blay, Jean-Yves
Maki, Robert G.
Van Tine, Brian A.
Alcindor, Thierry
Jones, Robin L.
D'Adamo, David R.
Guo, Matthew
Chawla, Sant
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (30) : 3433 - +
[44] Efficacy and Safety of Concurrent Chemoradiotherapy in ECOG 2 Patients with Locally Advanced Non-Small-Cell Lung Cancer: A Subgroup Analysis of a Randomized Phase III Trial
Bi, N.
Liu, L.
Liang, J.
Wu, S.
Chen, M.
Lv, C.
Zhao, L.
Shi, A.
Jiang, W.
Xu, Y.
Wang, L.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2019, 105 (01): : E496 - E497
[45] Efficacy and safety of concurrent chemoradiotherapy in ECOG 2 patients with locally advanced non-small-cell lung cancer: a subgroup analysis of a randomized phase III trial
Nan Bi
Lipin Liu
Jun Liang
Shixiu Wu
Ming Chen
Changxing Lv
Lujun Zhao
Anhui Shi
Wei Jiang
Yaping Xu
Zongmei Zhou
Jingbo Wang
Wenqing Wang
Dongfu Chen
Zhouguang Hui
Jima Lv
Hongxing Zhang
Qinfu Feng
Zefen Xiao
Xin Wang
Tao Zhang
Weibo Yin
Junling Li
Jie He
Luhua Wang
BMC Cancer, 20
[46] Efficacy and safety of concurrent chemoradiotherapy in ECOG 2 patients with locally advanced non-small-cell lung cancer: a subgroup analysis of a randomized phase III trial
Bi, Nan
Liu, Lipin
Liang, Jun
Wu, Shixiu
Chen, Ming
Lv, Changxing
Zhao, Lujun
Shi, Anhui
Jiang, Wei
Xu, Yaping
Zhou, Zongmei
Wang, Jingbo
Wang, Wenqing
Chen, Dongfu
Hui, Zhouguang
Lv, Jima
Zhang, Hongxing
Feng, Qinfu
Xiao, Zefen
Wang, Xin
Zhang, Tao
Yin, Weibo
Li, Junling
He, Jie
Wang, Luhua
BMC CANCER, 2020, 20 (01)
[47] Erratum to: Prolonged survival in patients with breast cancer and a history of brain metastases: results of a preplanned subgroup analysis from the randomized phase III BEACON trial
Javier Cortés
Hope S. Rugo
Ahmad Awada
Chris Twelves
Edith A. Perez
Seock–Ah Im
Patricia Gómez-Pardo
Lee S. Schwartzberg
Veronique Diéras
Denise A. Yardley
David A. Potter
Audrey Mailliez
Alvaro Moreno-Aspitia
Jin-Seok Ahn
Carol Zhao
Ute Hoch
Mary Tagliaferri
Alison L. Hannah
Joyce O’Shaughnessy
Breast Cancer Research and Treatment, 2017, 166 : 327 - 328
[48] Comorbidity, age and overall survival in patients with advanced pancreatic cancer - Results from NCIC CTG PA.3: A phase III trial of gemcitabine plus erlotinib or placebo
Vickers, M. M.
Powell, E. D.
Asmis, T. R.
Jonker, D. J.
Hilton, J. F.
O'Callaghan, C. J.
Tu, D.
Parulekar, W.
Moore, M. J.
EUROPEAN JOURNAL OF CANCER, 2012, 48 (10) : 1434 - 1442
[49] Prognostic and predictive impact of metastatic organ involvement on maintenance therapy in advanced metastatic colorectal cancer: Subgroup analysis of patients treated within the PanaMa trial (AIO KRK 0212)
Sommerhaeuser, Greta
Karthaus, Meinolf
Kurreck, Annika
Ballhausen, Alexej
Meyer-Knees, Johanna W.
Fruehauf, Stefan
Graeven, Ullrich
Mueller, Lothar
Koenig, Alexander O.
Weikersthal, Ludwig Fischer V.
Goekkurt, Eray
Haas, Siegfried
Stahler, Arndt
Heinemann, Volker
Held, Swantje
Alig, Annabel H. S.
Kasper-Virchow, Stefan
Stintzing, Sebastian
Trarbach, Tanja
Modest, Dominik P.
INTERNATIONAL JOURNAL OF CANCER, 2023, : 863 - 872
[50] Results From the Phase III Randomized Trial of Onartuzumab Plus Erlotinib Versus Erlotinib in Previously Treated Stage IIIB or IV Non-Small-Cell Lung Cancer: METLung
Spigel, David R.
Edelman, Martin J.
O'Byrne, Kenneth
Paz-Ares, Luis
Mocci, Simonetta
Phan, See
Shames, David S.
Smith, Dustin
Yu, Wei
Paton, Virginia E.
Mok, Tony
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04) : 412 - +

← 1 2 3 4 5 →